Eli Lilly (LLY) reachead $773.84 at the closing of the latest trading day, reflecting a -1.19% change compared to its last close.
Stocks splits have been a huge market theme in 2024, with big names across industries, from technology giant Nvidia to consumer stock Walmart completing such operations. Companies often launch this move after a long period of gains as a way to make their stock price more accessible to a wide range of investors.
If you're looking for top stocks, there's no need to reinvent the wheel. The Securities and Exchange Commission makes it a breeze to follow the world's greatest investors.
If you're too busy to keep monitoring your stock portfolio every other day, then investing in stocks that won't cause you a lot of headache down the road is a necessity. In order to do so, it's important to find reliable businesses that are also on a growth trajectory.
It seems like just yesterday that vaccines used to combat the COVID-19 pandemic were all anyone in the medical world could talk about. Companies such as Pfizer, Moderna, and Johnson & Johnson captured myriad headlines as each of these businesses played an integral role in the development of vaccines used to treat COVID-19.
Eli Lilly (LLY -0.08%) is generating billions in cash flow growth due to product innovation.
Missed out on giant S&P 500 winners this year like Nvidia and Eli Lilly? Don't worry: Analysts think you'll get another shot in 2025.
These three stocks, which are at or near the top of their respective industries, just increased dividends by double-digit percentages. Below, I'll reveal how much these companies are paying out to shareholders now.
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In this video, I will cover the recent updates regarding Novo Nordisk (NVO -17.83%) and whether or not the dip is worth buying over Eli Lilly (LLY 1.35%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one.
Eli Lilly (LLY 1.35%) soared more than 60% from the start of the year through its peak this summer, thanks to the company's dominance in one of today's most in-demand areas: the obesity drug market. Lilly sells tirzepatide, a compound sold for weight loss under the name Zepbound and for type 2 diabetes under the name Mounjaro.